- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02484768
IV Iron Treatment of Restless Legs Syndrome
A Phase II, Six-week, Randomised, Comparative, Double-blind Study of Intravenous Iron Isomaltoside 1000 Versus Placebo in Subjects With Restless Leg Syndrome With a 3 Month Extension
The purpose of this study is to to establish proof-of-concept for efficacy of iron isomaltoside 1000 in subjects with Restless Legs Syndrome.
The study is a randomised, comparative, double-blind study with a 3 months extension. Subjects with restless leg syndrome (RLS) will be randomised 2:1 to one of the following treat-ment groups:
- Group A (42 subjects): 1000 mg iron isomaltoside 1000
- Group B (21 subjects): Placebo infusion
Furthermore, non-responders, who continue to meet entry requirements, will receive 1000 mg iron isomaltoside 1000 at week 6.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
RLS is a disorder of sensation with a prevalence of around 2-5 % of the population. RLS is extremely responsive to dopaminergic agents, but a second issue is that iron deficiency states may precipitate RLS in as much as 25-30 % of subjects with iron deficiency. RLS appears to be related to deficits in brain iron content and metabolism. Magnetic resonance imaging (MRI) images demonstrate a decrease in substantia nigra and red nucleus iron content. The severity of this decrease in brain iron content is correlated with the severity of symptoms. A number of patients are quite resistant to dietary iron repletion but do resolve symptoms with high doses of intravenous (IV) iron.
For the individual subject, there will be 4 phases to the study which includes teleconferences (TCs) and 2 visits.
The treatment and treatment evaluation is the main study.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years
- Diagnosis of RLS based upon the CH-RLSq and HTDI
- IRLS score ≥ 15 at baseline evaluation when off RLS medications
- Willingness to participate and signing the informed consent form
Exclusion Criteria:
- S-ferritin > 300 ng/mL and/or TfS > 50 %
- Iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemo-siderosis)
- Known hypersensitivity to IV iron or any excipients in the investigational drug prod-ucts
- Pregnant or nursing women. In order to avoid pregnancy, women of childbearing po-tential have to use adequate contraception (e.g. intrauterine devices, hormonal contra-ceptives, or double barrier method) during the whole study period and 7 days after the last dosing
- History of active asthma within the last 5 years
- Decompensated liver cirrhosis or active hepatitis (defined as ASAT or ALAT > 3 times upper limit of normal)
- Active acute or chronic infections (assessed by clinical judgement supplied with WBC and CRP)
- Rheumatoid arthritis with symptoms or signs of active inflammation
- Pregnant or nursing women
- Previous IV iron treatment for RLS
- IV iron treatment within 1 year prior to screening
- Blood transfusion within 4 weeks prior to screening
- Planned elective surgery during the study
- Participation in any other interventional study where the study drug has not passed 5 half-lives prior to the screening
- Any other medical condition that, in the opinion of the Investigator, may cause the subject to be unsuitable for the completion of the study or place the subject at potential risk from being in the study, e.g. history of multiple allergies, a malignancy, uncon-trolled hypertension, unstable ischaemic heart disease, or uncontrolled diabetes melli-tus
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
Infusion of 1000 mg iron isomaltoside 1000 at baseline.
The infusion is diluted in 100 mL 0.9 % sodium chloride and given over approximately 15 min
|
Intravenous treatment
Other Names:
|
Placebo Comparator: Group B
Infusion of 100 mL 0.9 % sodium chloride at baseline given over approximately 15 min
|
Intravenous treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To measure the change in RLS symptoms from baseline to week 6 measured by the clinical global impression (CGI) score
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in RLS symptoms from baseline to week 4 and month 2 and 3 measured by the CGI score
Time Frame: 3 months
|
3 months
|
Change in RLS symptoms from baseline to week 4 and 6 and month 2 and 3 measured by the International Restless Legs Scale (IRLS)
Time Frame: from baseline to t = 12 weeks
|
from baseline to t = 12 weeks
|
Time from baseline to start of RLS medication
Time Frame: from baseline to t = 6 weeks
|
from baseline to t = 6 weeks
|
Time from baseline to start of RLS medication or non-response (CGI ≥ 3 at week 6)
Time Frame: from baseline to t = 6 weeks
|
from baseline to t = 6 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Type and incidence of adverse drug reactions (ADRs)
Time Frame: from baseline to t = 18 weeks
|
from baseline to t = 18 weeks
|
|
Number of adverse events (AEs) of special interest
Time Frame: from baseline to t = 18 weeks
|
(i.e.
hypersensitivity symptoms such as: urticaria, oedema, bronchospasm, hypotension, cardiorespiratory arrest, syn-cope, unresponsiveness, or loss of consciousness at pre-specified time points in relation to administration of study drug)
|
from baseline to t = 18 weeks
|
Change in haematology parameters, s-sodium, s-potassium, s-calcium, s-phosphate, s-urea, s-creatinine, s-albumin, s-bilirubin, aspartate aminotransferase (ASAT), and ala-nine aminotransferase (ALAT) from baseline to week 6 and month 3
Time Frame: from baseline to t = 18 weeks
|
from baseline to t = 18 weeks
|
|
Change in vital signs (heart rate and blood pressure) during drug administration
Time Frame: from baseline to t = 18 weeks
|
from baseline to t = 18 weeks
|
|
Clinical significant electrocardiogram (ECG) during drug administration
Time Frame: from baseline to t = 18 weeks
|
from baseline to t = 18 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Richard Allen, Assoc Prof, Johns Hopkins University Asthma& Allergy Bldg 1B76b 5501 Hopkins Bayview Blvd Baltimore, MD 21224 USA
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Nervous System Diseases
- Sleep Disorders, Intrinsic
- Dyssomnias
- Sleep Wake Disorders
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease
- Dyskinesias
- Psychomotor Disorders
- Parasomnias
- Syndrome
- Psychomotor Agitation
- Restless Legs Syndrome
- Hematinics
- Iron isomaltoside 1000
Other Study ID Numbers
- P-RLS-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Restless Legs Syndrome
-
Walter Reed National Military Medical CenterWithdrawnEkbom Syndrome | Restless Legs Syndrome, | Restless Legs,United States
-
GlaxoSmithKlineCompletedRestless Legs Syndrome | Restless Legs Syndrome (RLS)United States
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs Syndrome
-
XenoPort, Inc.CompletedRestless Legs Syndrome (RLS)United States
-
American Regent, Inc.CompletedRestless Legs Syndrome (RLS)United States
-
Astellas Pharma IncCompletedRestless Legs Syndrome (RLS)Japan
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs SyndromeJapan
-
UCB PharmaCompletedIdiopathic Restless Legs SyndromeGermany
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedIdiopathic Restless Legs SyndromeUnited States, Spain, Finland, Italy, Germany, Sweden, Austria, Netherlands, United Kingdom
-
American Regent, Inc.CompletedRestless Legs Syndrome (RLS)
Clinical Trials on Iron isomaltoside 1000
-
Pharmacosmos A/SCompleted
-
Pharmacosmos A/SCompletedInflammatory Bowel DiseaseDenmark
-
Seoul National University HospitalCompletedAnemia | Knee ArthropathyKorea, Republic of
-
Pharmacosmos A/SCompletedPatients With Chemotherapy Induced Anemia (CIA)United States
-
University of MalayaRecruitingAnemia | Post Partum HemorrhageMalaysia
-
Pharmacosmos A/SBioStataCompletedAnaemia in Chronic Kidney DiseaseSweden, United Kingdom
-
Pharmacosmos UK LtdBioStataCompletedIron Deficiency AnaemiaUnited Kingdom
-
Pharmacosmos A/SBioStataCompletedIron Deficiency AnemiaDenmark
-
Pharmacosmos A/SCompletedAnemia | Iron Metabolism Disorders | Deficiency Diseases | Anemia, Iron Deficiency | Hematologic DiseaseJapan
-
Pharmacosmos A/SCompleted